VBI Vaccines develops innovative vaccines for infectious diseases and cancer, including third-generation hepatitis B vaccine Sci-B-Vac®.

VBI Vaccines (NASDAQ:VBIV) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative vaccines for the prevention and treatment of infectious diseases and cancer. Their portfolio includes Sci-B-Vac®, a commercial third-generation hepatitis B vaccine, and an enveloped virus-like particle (eVLP) platform through which they develop vaccine candidates targeting cytomegalovirus (CMV), coronavirus (COVID-19), and other infectious diseases. VBI reflecting its commitment to advancing public health across global markets. The company aims to address some of the world's most pressing healthcare challenges by leveraging its expertise in vaccine research and development to bring new solutions to patients worldwide.
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift